6 results

• FDA Rejects Nuplazid Application for Treatment of Alzheimer’s Disease Psychosis

  August 8, 2022

  Russell Maas

  The FDA has rejected an application to approve Nuplazid to treat Alzheimer's disease psychosis.

• FDA Rejects Request To Expand Nuplazid Use For Symptoms of Dementia-Related Psychosis

  April 6, 2021

  Irvin Jackson

  Federal health regulators have rejected an application filed by Acadia Pharmaceuticals to expand the use of its blockbuster antipsychotic drug,...

• ISMP Report Questions Nuplazid Safety, FDA Approval And Lack Of Warnings

  March 29, 2019

  Irvin Jackson

  An ISMP report questions the FDA conclusions that there are no new safety signals with the Parkinson's disease psychosis drug, Nuplazid.

• Nuplazid Safety Risks May Lead FDA To Re-Review New Medication, Gottlieb Tells Senate

  April 26, 2018

  Irvin Jackson

  The FDA has launched a new safety review of the Parkinson's disease drug Nuplazid, FDA Commissioner Scott Gottlieb told Congress last week.

• Nuplazid Problems Linked To Hundreds Of Patient Deaths: Report

  April 11, 2018

  Irvin Jackson

  More than 700 deaths have been linked to Nuplazid side effects, raising concerns about the safety of the Parkinson's disease drug.

• Nuplazid Side Effects May Increase Parkinson’s Disease Hallucination Risks, ISMP Report Warns

  November 6, 2017

  Irvin Jackson

  The side effects of Nuplazid may increase the risk of hallucinations in some Parkinson's disease patients, according to the findings of a new report.